2023 Q1 Form 10-K Financial Statement
#000137251423000050 Filed on March 23, 2023
Income Statement
| Concept | 2023 Q1 | 2022 Q4 | 2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $1.269M | $2.778M | $8.278M |
| YoY Change | -23.75% | 101.44% | 55.49% |
| % of Gross Profit | |||
| Research & Development | $438.3K | $841.6K | $3.449M |
| YoY Change | -38.09% | -15.97% | -35.54% |
| % of Gross Profit | |||
| Depreciation & Amortization | $10.08K | $10.29K | $41.61K |
| YoY Change | -6.45% | -6.79% | -8.14% |
| % of Gross Profit | |||
| Operating Expenses | $1.917M | $2.635M | $12.31M |
| YoY Change | -46.3% | 38.34% | -27.35% |
| Operating Profit | -$1.917M | -$12.31M | |
| YoY Change | -46.3% | -27.35% | |
| Interest Expense | $33.47K | $24.48K | $8.599K |
| YoY Change | 15113.64% | -739.16% | 25.51% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $48.13K | -$940.00 | -$1.387M |
| YoY Change | 986.97% | -671.38% | |
| Pretax Income | -$1.869M | -$2.611M | -$13.70M |
| YoY Change | -47.59% | -56.08% | -17.98% |
| Income Tax | -$113.0K | -$113.0K | |
| % Of Pretax Income | |||
| Net Earnings | -$1.869M | -$2.498M | -$13.58M |
| YoY Change | -47.59% | -56.58% | -17.15% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | -$1.00 | -$18.55 | |
| Diluted Earnings Per Share | -$1.00 | -$1.76 | -$18.55 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 1.919M shares | 1.142M | 732.3K shares |
| Diluted Shares Outstanding | 1.863M shares | 732.3K shares |
Balance Sheet
| Concept | 2023 Q1 | 2022 Q4 | 2022 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $3.426M | $5.965M | $5.965M |
| YoY Change | -32.39% | -24.06% | -24.06% |
| Cash & Equivalents | $3.426M | $5.965M | $5.965M |
| Short-Term Investments | |||
| Other Short-Term Assets | $489.0K | $343.1K | $343.1K |
| YoY Change | -47.44% | -43.44% | -43.44% |
| Inventory | |||
| Prepaid Expenses | $489.0K | $343.1K | |
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $5.618M | $7.681M | $7.681M |
| YoY Change | -14.23% | -14.57% | -14.57% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $51.35K | $55.18K | $172.2K |
| YoY Change | -23.7% | -25.44% | -39.25% |
| Goodwill | $0.00 | ||
| YoY Change | |||
| Intangibles | $10.74M | $10.74M | |
| YoY Change | -0.23% | -0.23% | |
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $32.67K | $33.00K | $82.26K |
| YoY Change | -39.3% | -23.19% | -6.48% |
| Total Long-Term Assets | $10.91M | $11.00M | $11.00M |
| YoY Change | -1.59% | -1.27% | -1.27% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $5.618M | $7.681M | $7.681M |
| Total Long-Term Assets | $10.91M | $11.00M | $11.00M |
| Total Assets | $16.53M | $18.68M | $18.68M |
| YoY Change | -6.29% | -7.21% | -7.21% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $587.5K | $1.008M | $1.008M |
| YoY Change | 94.36% | 527.73% | 527.73% |
| Accrued Expenses | $1.182M | $1.836M | $1.758M |
| YoY Change | -35.53% | 38.03% | 23.8% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $2.156M | $3.272M | $3.272M |
| YoY Change | -14.5% | 103.3% | 103.3% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $3.527M | $3.309M | $3.309M |
| YoY Change | 15.46% | 5.4% | 5.4% |
| Total Long-Term Liabilities | $4.216M | $3.998M | $3.309M |
| YoY Change | 9.32% | 1.44% | 5.4% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $2.156M | $3.272M | $3.272M |
| Total Long-Term Liabilities | $4.216M | $3.998M | $3.309M |
| Total Liabilities | $6.372M | $7.271M | $7.271M |
| YoY Change | -0.1% | 30.97% | 30.97% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$136.3M | -$134.5M | |
| YoY Change | 9.53% | 11.24% | |
| Common Stock | $19.21K | $17.99K | |
| YoY Change | -84.83% | -85.8% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $10.16M | $11.41M | $11.41M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $16.53M | $18.68M | $18.68M |
| YoY Change | -6.29% | -7.21% | -7.21% |
Cashflow Statement
| Concept | 2023 Q1 | 2022 Q4 | 2022 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$1.869M | -$2.498M | -$13.58M |
| YoY Change | -47.59% | -56.58% | -17.15% |
| Depreciation, Depletion And Amortization | $10.08K | $10.29K | $41.61K |
| YoY Change | -6.45% | -6.79% | -8.14% |
| Cash From Operating Activities | -$3.070M | -$2.129M | -$10.43M |
| YoY Change | 8.37% | -33.42% | -4.22% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | $0.00 | |
| YoY Change | -100.0% | ||
| Acquisitions | $0.00 | ||
| YoY Change | -100.0% | ||
| Other Investing Activities | $0.00 | $0.00 | $6.380K |
| YoY Change | -100.0% | -100.0% | -106.85% |
| Cash From Investing Activities | $0.00 | $0.00 | $6.375K |
| YoY Change | -100.0% | -100.0% | -104.06% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | $513.2K | 3.243M | $8.621M |
| YoY Change | 4820.65% | -51.55% | |
| NET CHANGE | |||
| Cash From Operating Activities | -$3.070M | -2.129M | -$10.43M |
| Cash From Investing Activities | $0.00 | 0.000 | $6.375K |
| Cash From Financing Activities | $513.2K | 3.243M | $8.621M |
| Net Change In Cash | -$2.584M | 1.114M | -$1.886M |
| YoY Change | -7.31% | -134.55% | -128.28% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$3.070M | -$2.129M | -$10.43M |
| Capital Expenditures | $0.00 | $0.00 | |
| Free Cash Flow | -$2.129M | -$10.43M | |
| YoY Change | -33.42% | -4.78% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2022 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001372514 | |
| CY2022 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2022 | |
| CY2022 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2022 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2022Q3 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.025 | |
| CY2021Q3 | us-gaap |
Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
|
P5Y6M | |
| CY2022 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2022-12-31 | |
| CY2022 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2022 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2022Q2 | dei |
Entity Public Float
EntityPublicFloat
|
6117599 | usd |
| CY2023Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
1919270 | shares |
| CY2022 | dei |
Auditor Firm
AuditorFirmId
|
274 | |
| CY2022 | dei |
Auditor Name
AuditorName
|
EISNERAMPER LLP | |
| CY2022 | dei |
Auditor Location
AuditorLocation
|
Iselin, New Jersey | |
| CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5964556 | usd |
| CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
343069 | usd |
| CY2022Q4 | us-gaap |
Income Taxes Receivable
IncomeTaxesReceivable
|
1373041 | usd |
| CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
7680666 | usd |
| CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
55177 | usd |
| CY2022Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
49260 | usd |
| CY2022Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
10743164 | usd |
| CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
116992 | usd |
| CY2022Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
33000 | usd |
| CY2022Q4 | us-gaap |
Assets
Assets
|
18678259 | usd |
| CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1008262 | usd |
| CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1835934 | usd |
| CY2022Q4 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
322385 | usd |
| CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3272363 | usd |
| CY2022Q4 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
3309175 | usd |
| CY2022Q4 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
689121 | usd |
| CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
0 | usd |
| CY2022Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
3998296 | usd |
| CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
7270659 | usd |
| CY2022Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
| CY2022Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2021Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
1796472 | shares |
| CY2022 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8277993 | usd |
| CY2022 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | usd |
| CY2021 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
4037811 | usd |
| CY2022 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
582605 | usd |
| CY2022 | us-gaap |
Operating Expenses
OperatingExpenses
|
12309523 | usd |
| CY2022 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-12309523 | usd |
| CY2022 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
1425102 | usd |
| CY2021 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | usd |
| CY2022 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | usd |
| CY2021 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
278190 | usd |
| CY2022 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
4211 | usd |
| CY2021 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
0 | usd |
| CY2022 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
56891 | usd |
| CY2021 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1141 | usd |
| CY2022 | us-gaap |
Interest Expense
InterestExpense
|
8599 | usd |
| CY2021 | us-gaap |
Interest Expense
InterestExpense
|
6851 | usd |
| CY2022 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-14498 | usd |
| CY2021 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
0 | usd |
| CY2022 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1387097 | usd |
| CY2021 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
272480 | usd |
| CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-13696620 | usd |
| CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-13963288 | usd |
| CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-113010 | usd |
| CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-192603 | usd |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13770685 | usd |
| CY2022 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-18.55 | |
| CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-18.55 | |
| CY2021 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-57.12 | |
| CY2021 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-57.12 | |
| CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
732303 | shares |
| CY2022 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
732303 | shares |
| CY2021 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
241099 | shares |
| CY2021 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
241099 | shares |
| CY2022 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-96310 | usd |
| CY2021 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-85629 | usd |
| CY2022 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-13679920 | usd |
| CY2021 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-13856314 | usd |
| CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14579048 | usd |
| CY2022 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
462450 | usd |
| CY2022 | kprx |
Stock Issued During Period Value From Panoptes Hold Back Shares
StockIssuedDuringPeriodValueFromPanoptesHoldBackShares
|
0 | usd |
| CY2022 | kprx |
Adjustments To Additional Paid In Capital Reclassification Of Warrant Liability
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability
|
3674791 | usd |
| CY2022 | kprx |
Stock Adjusted During Period Value Reverse Stock Splits
StockAdjustedDuringPeriodValueReverseStockSplits
|
15629 | usd |
| CY2022 | kprx |
Adjustment To Additional Paid In Capital Warrant Issuance Costs
AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts
|
381360 | usd |
| CY2022 | kprx |
Stock Issued During Period Value Warrant Inducement
StockIssuedDuringPeriodValueWarrantInducement
|
2738831 | usd |
| CY2022 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
|
96310 | usd |
| CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13583610 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
11407600 | usd |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
9729741 | usd |
| CY2021 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
842475 | usd |
| CY2021 | kprx |
Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
|
50001 | usd |
| CY2021 | us-gaap |
Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
|
67936 | usd |
| CY2021 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
|
85629 | usd |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13770685 | usd |
| CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14579048 | usd |
| CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13583610 | usd |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13770685 | usd |
| CY2022 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
41609 | usd |
| CY2021 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
45296 | usd |
| CY2022 | kprx |
Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
|
92419 | usd |
| CY2021 | kprx |
Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
|
181977 | usd |
| CY2022 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
462450 | usd |
| CY2021 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
842475 | usd |
| CY2022 | kprx |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liabilities
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities
|
582605 | usd |
| CY2021 | kprx |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liabilities
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities
|
-505675 | usd |
| CY2022 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
1425102 | usd |
| CY2021 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | usd |
| CY2022 | us-gaap |
Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
|
-113010 | usd |
| CY2021 | us-gaap |
Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
|
-192603 | usd |
| CY2022 | kprx |
Cash Outflow From Loan Forgiveness
CashOutflowFromLoanForgiveness
|
0 | usd |
| CY2021 | kprx |
Cash Outflow From Loan Forgiveness
CashOutflowFromLoanForgiveness
|
278190 | usd |
| CY2022 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | usd |
| CY2021 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
4037811 | usd |
| CY2022 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
4211 | usd |
| CY2021 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
0 | usd |
| CY2022 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-275161 | usd |
| CY2021 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
156951 | usd |
| CY2022 | us-gaap |
Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
|
872736 | usd |
| CY2021 | us-gaap |
Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
|
441196 | usd |
| CY2022 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
22465 | usd |
| CY2021 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-14111 | usd |
| CY2022 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
782463 | usd |
| CY2021 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-310665 | usd |
| CY2022 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-103629 | usd |
| CY2021 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-181977 | usd |
| CY2022 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
609719 | usd |
| CY2021 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
40882 | usd |
| CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-10428133 | usd |
| CY2021 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-10675390 | usd |
| CY2022 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | usd |
| CY2021 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
63865 | usd |
| CY2022 | us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
0 | usd |
| CY2021 | us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
93155 | usd |
| CY2022 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
6375 | usd |
| CY2021 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
0 | usd |
| CY2022 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
6375 | usd |
| CY2021 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-157020 | usd |
| CY2022 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
5377719 | usd |
| CY2021 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
17745207 | usd |
| CY2022 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
2738831 | usd |
| CY2021 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
0 | usd |
| CY2022 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
520000 | usd |
| CY2021 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
50001 | usd |
| CY2022 | kprx |
Payments For Fractional Shares Related To Reverse Stock Split
PaymentsForFractionalSharesRelatedToReverseStockSplit
|
15629 | usd |
| CY2021 | kprx |
Payments For Fractional Shares Related To Reverse Stock Split
PaymentsForFractionalSharesRelatedToReverseStockSplit
|
0 | usd |
| CY2022 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
0 | usd |
| CY2021 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
212282 | usd |
| CY2022 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
8620921 | usd |
| CY2021 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
17582926 | usd |
| CY2022 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-85037 | usd |
| CY2021 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-81503 | usd |
| CY2022 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-1885874 | usd |
| CY2021 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
6669013 | usd |
| CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
7899690 | usd |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1230677 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
6013816 | usd |
| CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
7899690 | usd |
| CY2022 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
55415 | usd |
| CY2021 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
313312 | usd |
| CY2022 | kprx |
Grant Of Restricted Stock Awards
GrantOfRestrictedStockAwards
|
300 | usd |
| CY2021 | kprx |
Grant Of Restricted Stock Awards
GrantOfRestrictedStockAwards
|
0 | usd |
| CY2022 | us-gaap |
Nature Of Operations
NatureOfOperations
|
Business, Presentation and Recent Accounting Pronouncements<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of ophthalmic diseases. On November 5, 2021, Kiora Pharmaceuticals, Inc. (formerly known as EyeGate Pharmaceuticals, Inc.) (“Kiora” or the “Company”) filed with the Secretary of State of the State of Delaware, a Certificate of Ownership and Merger, merging its wholly-owned Delaware subsidiary, Kiora Pharmaceuticals, Inc., (incorporated in October 2021) into the Company and amending the Company’s certificate of incorporation to change its name to “Kiora Pharmaceuticals, Inc.” effective November 8, 2021 (the “Name Change”).</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company's lead product is KIO-301 with an initial focus on patients with later stages of disease progression due to Retinitis Pigmentosa (any and all sub-forms). KIO-301 is a potential vision-restoring small molecule that acts as a “photoswitch” specifically designed to restore vision in patients with inherited and age-related degenerative retinal diseases. The molecule is specifically designed to restore the eyes’ ability to perceive and interpret light in visually impaired patients. It selectively enters viable downstream retinal ganglion cells (no longer receiving electrical input due to degenerated rods and cones) and is intended to turn them into light sensing cells, capable of signaling the brain as to the presence or absence of light. The Company initiated a Phase 1b clinical trial in the third quarter of 2022. On March 17, 2022, the Company was granted Orphan Drug Designation from the U.S. FDA for the Active Pharmaceutical Ingredient (“API”) in KIO-301. KIO-301 (formerly known as B-203) was acquired through the Bayon Therapeutics, Inc. (“Bayon”) transaction which closed October 21, 2021.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">KIO-101 is a product that focuses on patients with Ocular Presentation of Rheumatoid Arthritis (“OPRA+”). KIO-101 is a next-generation, non-steroidal, immune-modulatory and small-molecule inhibitor of Dihydroorotate Dehydrogenase (“DHODH”) with what the Company believes to be best-in-class picomolar potency and a validated immune modulating mechanism designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In the fourth quarter of 2021, the Company reported top-line safety and tolerability from a phase 1b proof-of-concept (“POC”) study evaluating KIO-101 in patients with ocular surface inflammation. The Company expects to initiate a Phase 2 clinical trial in the first quarter of 2023. KIO-101 (formerly known as PP-001) was acquired through the acquisition of Panoptes Pharma Ges.m.b.H “Panoptes” in the fourth quarter of 2020.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition, the Company is developing KIO-201, for patients with Persistent Corneal Epithelial Defects ("PCED"), which is an orphan disease and as such, the Company is currently seeing orphan drug designation. The Company is also evaluating KIO-201 in patients recovering from surgical wounds, such as those undergoing photorefractive keratectomy ("PRK") surgery for corneal wound repair after refractive surgery. KIO-201 is a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve and maintain ocular surface integrity. KIO-201 has unique properties that help hydrate and protect the ocular surface. The Company is currently evaluating KIO-201 in a Phase 2 clinical trial in patients with PCEDs and released top-line data in Q1 2023. We expect to release full data in Q2 2023. The Company is in planning stages of a Phase 3b trial for patients recovering from the laser vision correction procedure PRK and plans to initiate the study before the end of 2023.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Since its inception, Kiora has devoted substantially all of its efforts to business planning, research and development, and raising capital.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The accompanying Consolidated Financial Statements have been prepared assuming that Kiora will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">course of business. At December 31, 2022, Kiora had unrestricted Cash and Cash Equivalents of $6.0 million, and an Accumulated Deficit of $134.5 million. Kiora has incurred losses and negative cash flows since inception, and future losses are anticipated. Based on its cash on hand at December 31, 2022, the Company anticipates having sufficient cash to fund planned operations into July 2023, however, the acceleration or reduction of cash outflows by Company management can significantly impact the timing for the need to raise additional capital to complete development of its products. To continue development, Kiora will need to raise additional capital through equity financing, license agreements, and/or additional U.S. government grants. Although historically the Company has been successful at raising capital, most recently raising net proceeds of approximately $2.7 million in a warrant inducement transaction that closed on November 22, 2022, net of placement agent fees of $0.3 million and expense of $0.1 million, additional capital may not be available on terms favorable to Kiora, if at all. The Company does not know if any future offerings will succeed. Accordingly, no assurances can be given that Company management will succeed in these endeavors. The Company’s recurring losses from operations have caused management to determine there is substantial doubt about the Company’s ability to continue as a going concern. The Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Reverse Stock Split</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">On September 23, 2022, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a one-for-forty (1-for-40) reverse stock split of its outstanding common stock. The Amendment was approved by the Company’s stockholders at the Company’s 2022 Annual Meeting of Stockholders held on September 23, 2022, and by the Company’s board of directors. The Amendment became effective on September 27, 2022.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The reverse stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective time of the Amendment. As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options, and restricted stock awards issued by the Company and outstanding immediately prior to the effective time of the Amendment, which resulted in a proportionate decrease in the number of shares of the Company’s common stock reserved for issuance upon exercise or vesting of such stock options, and restricted stock awards, and, in the case of stock options, a proportionate increase in the exercise price of all such stock options. In addition, the number of shares reserved for issuance under the Company’s equity compensation plans immediately prior to the effective time of the Amendment was reduced proportionately. The reverse stock split did not affect the number of shares or par value of common stock authorized for issuance under the Company’s Amended and Restated Certificate of Incorporation, which remained at 50,000,000 shares.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">No fractional shares were issued as a result of the reverse stock split. Stockholders of record who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof. The reverse stock split affected all stockholders proportionately and did not affect any stockholder’s percentage ownership of the Company’s common stock (except to the extent that the reverse stock split results in any stockholder owning only a fractional share). As a result of the reverse stock split, the number of the Company’s outstanding shares of common stock as of September 27, 2022 decreased from 43,163,123 (pre-split) shares to 1,079,045 (post-split) shares.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">All share and per share amounts in the accompanying financial statements and related footnotes have been adjusted retroactively to reflect the reverse stock split as if it had occurred at the beginning of the earliest period presented. While the number of warrants outstanding did not change, the underlying shares did and are presented reflecting the split. The Company’s common stock began trading on The Nasdaq Capital Market on a split-adjusted basis when the market opened on September 27, 2022.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption of Accounting Standards</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. This guidance removes the liability and equity separation models for convertible instruments with a cash conversion feature or beneficial conversion feature. As a result, companies will more likely account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account). In addition, the guidance simplifies the settlement assessment that issuers perform to determine whether a contract in their own equity qualifies for equity classification. Finally, the guidance requires entities to use the if-converted method to calculate earnings per share for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 on January 1, 2022. The adoption of ASU 2020-06 did not have a material effect for the Company.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) to clarify an issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. Specifically, the ASU provides a principles-based framework to determine whether an issuer should recognize the modification or exchange as an adjustment to equity or an expense. The guidance is effective for annual reporting periods beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2021-04 on January 1, 2022. The adoption of ASU 2021-04 did not have a material effect for the Company.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In November 2021, the FASB issued ASU 2021-10, which requires business entities to disclose information about certain government assistance they receive. Such disclosure requirements include the nature of the transactions and the related accounting policy used, the line items on the balance sheet and income statement that are affected and the amounts applicable to each financial statement line item and significant terms and conditions of the transactions. ASU 2021-10 was effective for the Company January 1, 2022. The adoption of ASU 2021-10 did not have a material effect for the Company.</span></div> | |
| CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
6000000 | usd |
| CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-134500000 | usd |
| CY2022Q4 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
2700000 | usd |
| CY2022Q4 | kprx |
Warrant Issuance Placement Agent Fees
WarrantIssuancePlacementAgentFees
|
300000 | usd |
| CY2022Q4 | kprx |
Adjustment To Additional Paid In Capital Warrant Issuance Costs
AdjustmentToAdditionalPaidInCapitalWarrantIssuanceCosts
|
100000 | usd |
| CY2022Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | shares |
| CY2022Q3 | kprx |
Stockholders Equity Note Reverse Stock Split Number Of Fractional Shares Issued
StockholdersEquityNoteReverseStockSplitNumberOfFractionalSharesIssued
|
0 | shares |
| CY2022Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
43163123 | shares |
| CY2022Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
1079045 | shares |
| CY2022 | kprx |
Number Of Board Of Directors Who Are Also Executives At A Related Party
NumberOfBoardOfDirectorsWhoAreAlsoExecutivesAtARelatedParty
|
1 | director |
| CY2021 | kprx |
Related Party Transactions Number Of Vendors
RelatedPartyTransactionsNumberOfVendors
|
1 | vendor |
| CY2022 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The Company makes significant estimates and assumptions in recording the accruals for the Company’s clinical trial and research activities, establishing the useful lives of intangible assets and property and equipment, conducting impairment reviews of goodwill, in-process research and development (IPR&D), stock-based compensation, assumptions used to value warrants including warrant modifications and </span></div>inducements, and contingent considerations payable. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company monitors and regularly assesses these estimates, actual results could differ significantly from these estimates. The Company records changes in estimates in the period that it becomes aware of the change. | |
| CY2022Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
49300 | usd |
| CY2021Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
45000 | usd |
| CY2021 | kprx |
Related Party Transactions Number Of Universities
RelatedPartyTransactionsNumberOfUniversities
|
2 | university |
| CY2022 | us-gaap |
Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
|
0 | usd |
| CY2022Q4 | us-gaap |
Goodwill
Goodwill
|
0 | usd |
| CY2022Q4 | us-gaap |
Goodwill
Goodwill
|
0 | usd |
| CY2021Q4 | us-gaap |
Goodwill
Goodwill
|
0 | usd |
| CY2021 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
4000000 | usd |
| CY2021Q4 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
|
10600000 | usd |
| CY2022Q4 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
|
10600000 | usd |
| CY2021 | kprx |
Related Party Transactions Number Of Consultants
RelatedPartyTransactionsNumberOfConsultants
|
6 | consultant |
| CY2022 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment |
| CY2022 | kprx |
Number Of Geographic Segments
NumberOfGeographicSegments
|
3 | segment |
| CY2022Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
700000 | usd |
| CY2021Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
800000 | usd |
| CY2022Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | usd |
| CY2022Q4 | us-gaap |
Income Tax Receivable
IncomeTaxReceivable
|
1300000 | usd |
| CY2021Q4 | us-gaap |
Income Tax Receivable
IncomeTaxReceivable
|
500000 | usd |
| CY2022 | kprx |
Related Party Transactions Number Of Vendors
RelatedPartyTransactionsNumberOfVendors
|
1 | vendor |
| CY2022 | kprx |
Related Party Transactions Number Of Consultants
RelatedPartyTransactionsNumberOfConsultants
|
6 | consultant |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
30000 | shares |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
375 | shares |
| CY2022 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1712409 | shares |
| CY2021 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
182313 | shares |
| CY2021 | us-gaap |
Increase Decrease In Fair Value Adjustments On Assets And Liabilities Carried At Fair Value Under Fair Value Option
IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption
|
0 | usd |
| CY2022 | us-gaap |
Increase Decrease In Fair Value Adjustments On Assets And Liabilities Carried At Fair Value Under Fair Value Option
IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption
|
0 | usd |
| CY2022Q4 | kprx |
Change In Contingent Consideration Fair Value
ChangeInContingentConsiderationFairValue
|
600000 | usd |
| CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
172496 | usd |
| CY2021Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
187131 | usd |
| CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
117319 | usd |
| CY2021Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
113132 | usd |
| CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
55177 | usd |
| CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
73999 | usd |
| CY2022 | us-gaap |
Depreciation
Depreciation
|
16596 | usd |
| CY2021 | us-gaap |
Depreciation
Depreciation
|
20296 | usd |
| CY2022Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1312443 | usd |
| CY2021Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
937970 | usd |
| CY2022Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
282721 | usd |
| CY2021Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
194425 | usd |
| CY2022Q4 | kprx |
Clinical Trials Current
ClinicalTrialsCurrent
|
57020 | usd |
| CY2021Q4 | kprx |
Clinical Trials Current
ClinicalTrialsCurrent
|
168785 | usd |
| CY2022Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
183750 | usd |
| CY2021Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
28961 | usd |
| CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1835934 | usd |
| CY2021Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1330141 | usd |
| CY2020Q2 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
300000 | usd |
| CY2022 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
25000 | usd |
| CY2021 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
25000 | usd |
| CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
25000 | usd |
| CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
25000 | usd |
| CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
25000 | usd |
| CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
25000 | usd |
| CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
25000 | usd |
| CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
18750 | usd |
| CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
143750 | usd |
| CY2021Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
38278 | shares |
| CY2021Q1 | kprx |
Class Of Warrant Or Right Number Of Warrant Issued
ClassOfWarrantOrRightNumberOfWarrantIssued
|
38278 | shares |
| CY2021Q1 | kprx |
Share Purchase Price Of Common Stock And Warrant
SharePurchasePriceOfCommonStockAndWarrant
|
209.00 | |
| CY2021Q1 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
8000000 | usd |
| CY2021Q1 | kprx |
Warrant Exercise Price Per Share Subject To Adjustment
WarrantExercisePricePerShareSubjectToAdjustment
|
209.00 | |
| CY2021Q1 | kprx |
Warrant Term
WarrantTerm
|
P5Y | |
| CY2021Q3 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
116721 | shares |
| CY2021Q3 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
92.10 | |
| CY2021Q3 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
5836 | shares |
| CY2021Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
115.124 | |
| CY2021Q3 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
9800000 | usd |
| CY2021Q3 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
273 | shares |
| CY2010Q4 | us-gaap |
Excess Stock Shares Authorized
ExcessStockSharesAuthorized
|
59414 | shares |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
6249 | shares |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
840.88 | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P2Y3M18D | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
8654 | shares |
| CY2021 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
164.30 | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
825 | shares |
| CY2021 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
1046 | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
1124 | shares |
| CY2021 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
259.70 | |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
12954 | shares |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
426.25 | |
| CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P5Y6M21D | |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
5087 | shares |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
847.31 | |
| CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P3Y1M2D | |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
12954 | shares |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
426.25 | |
| CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P5Y6M21D | |
| CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
78641 | shares |
| CY2022 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
8.49 | |
| CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
14 | shares |
| CY2022 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
842.57 | |
| CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
6830 | shares |
| CY2022 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
446.34 | |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
84751 | shares |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
36.92 | |
| CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P9Y7M2D | |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
4939 | shares |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
442.52 | |
| CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P7Y3M7D | |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
84751 | shares |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
36.92 | |
| CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P9Y7M2D | |
| CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
78641 | shares |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
8654 | shares |
| CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0242 | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0182 | |
| CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y | |
| CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P10Y | |
| CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.40 | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.40 | |
| CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
27.08 | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
145.63 | |
| CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.2100 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.2100 | |
| CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
-0.0259 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.0335 | |
| CY2022 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-113010 | usd |
| CY2021 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-192603 | usd |
| CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
462450 | usd |
| CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
842475 | usd |
| CY2022 | kprx |
Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Fair Values
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues
|
600000 | usd |
| CY2021 | kprx |
Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Fair Values
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValues
|
1200000 | usd |
| CY2022Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
900000 | usd |
| CY2021Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
1000000 | usd |
| CY2022 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y6M | |
| CY2021 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y3M18D | |
| CY2022Q4 | kprx |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue
|
0 | usd |
| CY2021Q4 | kprx |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue
|
0 | usd |
| CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-10563302 | usd |
| CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-10639818 | usd |
| CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-3133318 | usd |
| CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-3323470 | usd |
| CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-13696620 | usd |
| CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-13963288 | usd |
| CY2022 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
4954 | usd |
| CY2021 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-24086 | usd |
| CY2022 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
-117964 | usd |
| CY2021 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
-168517 | usd |
| CY2022 | us-gaap |
Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
|
-113010 | usd |
| CY2021 | us-gaap |
Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
|
-192603 | usd |
| CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
|
-0.0924 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
|
0.0072 | |
| CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
|
0 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
|
0.0607 | |
| CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.0953 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.2133 | |
| CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.0058 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.0109 | |
| CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
0.0289 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
0.0100 | |
| CY2022 | kprx |
Effective Income Tax Rate Reconciliation State Non Income Based Tax Percent
EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent
|
0 | |
| CY2021 | kprx |
Effective Income Tax Rate Reconciliation State Non Income Based Tax Percent
EffectiveIncomeTaxRateReconciliationStateNonIncomeBasedTaxPercent
|
0.0001 | |
| CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.0026 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0.0161 | |
| CY2022 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.0284 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.0138 | |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
22809667 | usd |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
20689134 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
2925890 | usd |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
2853598 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
4606902 | usd |
| CY2021Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
5640428 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
782355 | usd |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
835432 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
|
336360 | usd |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
|
128188 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
31461174 | usd |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
30146780 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
29593286 | usd |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
28298339 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
1867888 | usd |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
1848441 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
477 | usd |
| CY2021Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
956 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
|
2556532 | usd |
| CY2021Q4 | us-gaap |
Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
|
2649616 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
689121 | usd |
| CY2021Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
802131 | usd |
| CY2022Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
80500000 | usd |
| CY2022 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
1300000 | usd |
| CY2021 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
3000000 | usd |
| CY2022Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | usd |
| CY2021Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | usd |
| CY2022 | kprx |
Lessee Number Of Operating Leases
LesseeNumberOfOperatingLeases
|
3 | operatinglease |
| CY2022 | kprx |
Cease Payments Not Yet Paid Based On Prevailing Financial Market Conditions
CeasePaymentsNotYetPaidBasedOnPrevailingFinancialMarketConditions
|
0.10 | |
| CY2022 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
100000 | usd |
| CY2021 | kprx |
Operating Lease Interest On Lease Liabilities
OperatingLeaseInterestOnLeaseLiabilities
|
200000 | usd |
| CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
|
105523 | usd |
| CY2022 | kprx |
Number Of License Agreements
NumberOfLicenseAgreements
|
7 | licenseagreement |
| CY2020Q2 | kprx |
Payment Of Annual Fee
PaymentOfAnnualFee
|
5000 | usd |
| CY2022 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
|
0 | |
| CY2021 | us-gaap |
Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
|
29200 | usd |
| CY2022Q4 | kprx |
Defined Benefit Plan Contributions By Employer Accrued
DefinedBenefitPlanContributionsByEmployerAccrued
|
8500 | usd |
